Grifols SA ADR

Stock Chart, Company Information, and Scan Results

$10.85(as of Jul 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Grifols SA ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$10.85
Ticker SymbolGRFS
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - General
Employees23,800
CountyUSA
Market Cap$8,833.5M
EBIDTA1,665.7M
10-Day Moving Average10.02
P/E Ratio45.53
20-Day Moving Average9.68
Forward P/E Ratio12.27
50-Day Moving Average9.00
Earnings per Share0.27
200-Day Moving Average8.06
Profit Margin3.49%
RSI72.92
Shares Outstanding258.2M
ATR0.33
52-Week High10.50
Volume3,647,605
52-Week Low6.19
Most Recent Support Level9.66
Book Value8,607.0M
Most Recent Resistance Level10.17
P/B Ratio0.83
Upper Keltner10.42
P/S Ratio0.99
Lower Keltner8.95
Debt-to-Equity Ratio10.42
Next Earnings Date11/06/2025
Cash Surplus-1,176.4M
Next Ex-Dividend DateUnknown

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Grifols SA ADR In Our Stock Scanner

As of Jul 30, 2025
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Bull FlagScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.